Friday, December 30, 2011 11:06:45 AM
Today is the shorting elements last ditch effort to keep the price down. I am almost certain the company ATRN will prepare a mega-counter attack in January. No company is going allow or tolerate having their equity stolen from them so blatantly.
ATRN will easily rebound to .08 or more next month.
It is an obvious play to me. In the meantime, some sellers are going to be spooked by the cheap tricks of the shorters and sell when 500 shares are sold to the bid, and other cheap games are played, on and off this board.
But that always is the case before a rebound and as a squeeze trigger begins to take fold. The fact is, ATRN is setting up for mother of all squeeze triggers and I am sure many of those who have been shorting ATRN are looking for ways out. Wait until they are squeezed into covering.
ATRN was 60 to 70 cents in the first week of November, less than two months ago. Nice profit for the longs when ATRN eventually returns to those levels, devastation for the shorters who are going to pay dearly for their attempted thievery.
ATRN will easily rebound to .08 or more next month.
It is an obvious play to me. In the meantime, some sellers are going to be spooked by the cheap tricks of the shorters and sell when 500 shares are sold to the bid, and other cheap games are played, on and off this board.
But that always is the case before a rebound and as a squeeze trigger begins to take fold. The fact is, ATRN is setting up for mother of all squeeze triggers and I am sure many of those who have been shorting ATRN are looking for ways out. Wait until they are squeezed into covering.
ATRN was 60 to 70 cents in the first week of November, less than two months ago. Nice profit for the longs when ATRN eventually returns to those levels, devastation for the shorters who are going to pay dearly for their attempted thievery.
Recent PTIX News
- Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114 • ACCESS Newswire • 03/17/2026 12:00:00 PM
- Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market • ACCESS Newswire • 03/10/2026 12:00:00 PM
- Results from Phase 1 Multiple-Dose Study of PT00114 • ACCESS Newswire • 12/09/2025 01:46:00 PM
- Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice • ACCESS Newswire • 11/27/2025 08:45:00 AM
- Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study • ACCESS Newswire • 11/13/2025 01:22:00 PM
- Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates • GlobeNewswire Inc. • 07/30/2025 12:30:00 PM

